Keratoconus Treatment Companies
Keratoconus is a progressive eye disorder that results in the thinning and reshaping of the cornea, leading to distorted vision. Treatment options range from eyeglasses and contact lenses to surgical interventions.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Keratoconus Treatment Companies Update
-
October 2023: EpiSmartTM, Epion's minimally invasive keratoconus treatment, has entered Phase 3 Apricity studies, the firm reported. This is a major step forward in the company's efforts to revolutionize the care for keratoconus. EpiSmart is a drug-device combination being studied for the treatment of keratoconus using epithelium-on cross-linking. Recent research suggests that keratoconus, a bilateral progressive corneal condition that can lead to irreversible vision loss, is more common in Africa and the Middle East than in the United States, where an estimated 3 million people suffer from it. Building on the positive results seen in Phase 2 clinical trials, the Apricity studies will assess the safety and effectiveness of EpiSmart through randomization, masking, and placebo control.
-
July 2023: Epion Therapeutics, Inc. is the proud new name for CXL Ophthalmics, Inc., a pioneer in the treatment of corneal diseases. The new name better reflects the company's goal to provide a therapy for keratoconus that is both the safest and least intrusive in the globe. Epion's Phase 3 Trials of the EpiSmartTM System will not begin unless this plan and strategy are in place. The ability to maintain functional eyesight may be preserved with prompt diagnosis and treatment. Epion Therapeutics is at the forefront of early intervention, which aims to treat patients immediately upon diagnosis rather than waiting for the disease to worsen. Through rigorous scientific research, Epion is reinventing the standard of treatment for keratoconus. Epion is developing a technique that will not harm the corneal epithelium in any way (chemically or physically). Recovery time, patient pain, and infection risk may all be reduced using Epion's novel methodology compared to both conventional epi-off and cutting-edge epi-on cross-linking techniques
List of Keratoconus Treatment Key companies in the market
- HOYA vision care company,
- Menicon Co., Ltd.,
- Cooper companies Inc.,
- Baush Health,
- SynergEyes,
- Carl Zeiss Meditec AG,
- Contamac,
- Seed Co., Ltd.,
- Novartis AG,
- Johnson & Johnson Services, Inc.
Â
Keratoconus Treatment Market Highlights:
Keratoconus Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
